PE20190104A1 - Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos - Google Patents

Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos

Info

Publication number
PE20190104A1
PE20190104A1 PE2018001985A PE2018001985A PE20190104A1 PE 20190104 A1 PE20190104 A1 PE 20190104A1 PE 2018001985 A PE2018001985 A PE 2018001985A PE 2018001985 A PE2018001985 A PE 2018001985A PE 20190104 A1 PE20190104 A1 PE 20190104A1
Authority
PE
Peru
Prior art keywords
seq
antigens
compositions
chagas
antibodies
Prior art date
Application number
PE2018001985A
Other languages
English (en)
Inventor
Mateo Olga Pleguezuelos
Wilson Romero Caparros-Wanderley
Gregory Alan Stoloff
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of PE20190104A1 publication Critical patent/PE20190104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Referido a antigenos de Trypanosoma cuya secuencia es seleccionada de SEC ID NO: 6, SEC ID NO: 9, SEC ID NO: 5, SEC ID NO: 7, SEC ID NO: 8, SEC ID NO: 11, SEC ID NO: 1, SEC ID NO: 2, SEC ID NO: 3, SEC ID NO: 4, SEC ID NO: 10 o SEC ID NO: 12, o un peptido con 75% de identidad de aminoacidos de las secuencias citadas. Tambien se refiere a composiciones inmunogenicas que comprenden uno o mas de los antigenos descritos para tratar enfermedades basadas en Trypanosoma
PE2018001985A 2016-04-14 2017-04-18 Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos PE20190104A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662322770P 2016-04-14 2016-04-14

Publications (1)

Publication Number Publication Date
PE20190104A1 true PE20190104A1 (es) 2019-01-15

Family

ID=58671580

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001985A PE20190104A1 (es) 2016-04-14 2017-04-18 Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos

Country Status (18)

Country Link
US (2) US10973897B2 (es)
EP (1) EP3442569A1 (es)
JP (1) JP2019513797A (es)
KR (1) KR20190039022A (es)
CN (2) CN116059330A (es)
AU (1) AU2017248680A1 (es)
BR (1) BR112018071108A2 (es)
CA (1) CA3020856A1 (es)
CL (2) CL2018002932A1 (es)
CO (1) CO2018012295A2 (es)
CU (1) CU20180127A7 (es)
EC (1) ECSP18079073A (es)
MX (1) MX2018012504A (es)
NI (1) NI201800105A (es)
PE (1) PE20190104A1 (es)
RU (1) RU2018139865A (es)
SG (1) SG11201808915YA (es)
WO (1) WO2017178660A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2594637B (en) * 2019-01-07 2023-08-02 Genome Res Ltd Novel trypanosomal vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2731370A1 (de) * 1977-07-12 1979-01-25 Behringwerke Ag Chagas impfstoff und verfahren zu dessen herstellung
ES2169995B1 (es) 2000-04-17 2003-12-01 Leti Lab Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
US9804158B2 (en) 2013-07-02 2017-10-31 Institut De Recherche Pour Le Développement Peptides and methods for the detection of Leishmaniasis
US9566320B2 (en) 2013-09-24 2017-02-14 The Board Of Regents Of The University Of Texas System Mucin-associated surface protein as vaccine against Chagas disease

Also Published As

Publication number Publication date
CN116059330A (zh) 2023-05-05
AU2017248680A1 (en) 2018-11-22
ECSP18079073A (es) 2019-02-28
EP3442569A1 (en) 2019-02-20
WO2017178660A1 (en) 2017-10-19
CN109310747A (zh) 2019-02-05
CL2021001441A1 (es) 2021-11-19
MX2018012504A (es) 2019-08-29
CA3020856A1 (en) 2017-10-19
JP2019513797A (ja) 2019-05-30
BR112018071108A2 (pt) 2019-02-26
WO2017178660A9 (en) 2017-12-07
CU20180127A7 (es) 2019-08-06
US20210220453A1 (en) 2021-07-22
SG11201808915YA (en) 2018-11-29
NI201800105A (es) 2019-02-18
US10973897B2 (en) 2021-04-13
US20170296637A1 (en) 2017-10-19
CL2018002932A1 (es) 2019-02-01
KR20190039022A (ko) 2019-04-10
CN109310747B (zh) 2022-11-22
CO2018012295A2 (es) 2019-04-30
RU2018139865A (ru) 2020-05-14

Similar Documents

Publication Publication Date Title
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
EA201892250A1 (ru) Вакцина против rsv
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
EA201990071A1 (ru) Композиция пептидной вакцины
AR104809A1 (es) Anticuerpos anti-cd40 y usos de los mismos
DOP2016000051A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos.
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
AR101871A1 (es) Composiciones de glicoconjugado inmunogénico / terapéutico y sus usos
EA201791907A1 (ru) Бивалентная вакцина против вируса свиного гриппа
EA201892702A1 (ru) Стабилизированные f-белки rsv до слияния
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
BR112016016103A2 (pt) Composição de antígenos micobacterianos
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017016110A2 (pt) composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição

Legal Events

Date Code Title Description
FA Abandonment or withdrawal